Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43801   clinical trials with a EudraCT protocol, of which   7264   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-000401-36
    Sponsor's Protocol Code Number:DSC/14/2357/48
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2017-02-10
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2016-000401-36
    A.3Full title of the trial
    Randomised, double blind, placebo controlled, multicentre study to evaluate the efficacy and safety of givinostat in ambulant patients with Duchenne Muscular Dystrophy.
    Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de givinostat en pacientes ambulantes con distrofia muscular de Duchenne (DMD)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Study to evaluate the efficacy and safety of givinostat in ambulant patients with Duchenne Muscular Dystrophy.
    Estudio para evaluar la eficacia y la seguridad de givinostat en pacientes ambulantes con distrofia muscular de Duchenne (DMD)
    A.4.1Sponsor's protocol code numberDSC/14/2357/48
    A.5.4Other Identifiers
    Name:INDNumber:126598
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorITALFARMACO S.p.A.
    B.1.3.4CountryItaly
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportITALFARMACO S.p.A.
    B.4.2CountryItaly
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationITALFARMACO S.p.A.
    B.5.2Functional name of contact pointClinical Research and Development
    B.5.3 Address:
    B.5.3.1Street AddressVia dei Lavoratori, 54
    B.5.3.2Town/ cityCinisello Balsamo (MI)
    B.5.3.3Post code20092
    B.5.3.4CountryItaly
    B.5.4Telephone number+3491 657 23 23
    B.5.5Fax number+3491 657 23 66
    B.5.6E-mailp.bettica@italfarmaco.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/12/1009
    D.3 Description of the IMP
    D.3.1Product nameGivinostat (hydrochloride monohydrate)
    D.3.2Product code ITF2357
    D.3.4Pharmaceutical form Oral suspension
    D.3.4.1Specific paediatric formulation Yes
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNGivinostat (hydrochloride monohydrate)
    D.3.9.1CAS number 732302-99-7
    D.3.9.2Current sponsor codeITF2357
    D.3.9.3Other descriptive nameGIVINOSTAT
    D.3.9.4EV Substance CodeSUB30834
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboOral suspension
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Duchenne Muscular Dystrophy (DMD)
    Distrofia muscular de Duchenne (DMD)
    E.1.1.1Medical condition in easily understood language
    A neuromuscular disease characterized by rapidly progressive muscle weakness and wasting
    Una enfermedad neuromuscular caracterizada por debilidad y desgaste muscular de rápida progresión.
    E.1.1.2Therapeutic area Diseases [C] - Musculoskeletal Diseases [C05]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.1
    E.1.2Level PT
    E.1.2Classification code 10013801
    E.1.2Term Duchenne muscular dystrophy
    E.1.2System Organ Class 10010331 - Congenital, familial and genetic disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To establish the effects of givinostat versus placebo administered chronically over 18 months to slow disease progression in ambulant DMD subjects
    Establecer los efectos de givinostat en comparación con placebo cuando se administra de forma crónica durante más de 18 meses para frenar la progresión de la enfermedad en pacientes ambulantes con DMD.
    E.2.2Secondary objectives of the trial
    To assess the safety and tolerability of givinostat versus placebo administered chronically in DMD subjects.
    To evaluate the pharmacokinetic (PK) profile of givinostat administered chronically in the target population.
    To evaluate the impact on quality of life and activities of daily living of givinostat versus placebo administered chronically.

    Exploratory objectives:
    To evaluate the correlation between PK profile of givinostat and pharmacodynamics (PD) data.
    To explore whether the effects of givinostat versus placebo administered chronically may be related to the type of DMD mutation or to the biomarkers.
    • Evaluar la seguridad y tolerabilidad de givinostat en comparación con placebo cuando se administra de forma crónica en pacientes con DMD.
    • Evaluar el perfil farmacocinético (FC) de givinostat cuando se administra de forma crónica en la población del estudio;
    • Evaluar el impacto sobre la calidad de vida y las actividades cotidianas de givinostat en comparación con placebo cuando se administra de forma crónica.

    Objetivos exploratorios secundarios:
    • Evaluar la correlación entre el perfil FC de givinostat y los datos de farmacodinámica (FD);
    • Explorar si los efectos de givinostat en comparación con placebo cuando se administra de forma crónica podrían estar relacionados con el tipo de mutación de DMD o los biomarcadores.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Are ambulant males aged ≥6 years at randomisation with DMD characteristic clinical symptoms or signs (e.g., proximal muscle weakness, Gowers’ maneuver, elevated serum creatinine kinase level) already present at screening;
    2. Have DMD diagnosis confirmed by genetic testing;
    3. Are able to give informed assent and/or consent in writing signed by the subject and/or parent/legal guardian (according to local regulations);
    4. Are able to complete 2 Four Stairs Climb test (4SC) screening assessments; the results of these tests must be within ±1 second of each other;
    5. Have the mean of 2 screening 4SC assessments ≤8 seconds;
    6. Have time to rise from floor of <10 seconds at screening;
    7. Have manual muscle testing (MMT) of quadriceps at screening ≥ Grade 3;
    8. Are eligible according to the protocol-specified functional algorithm predictive of vastus lateralis muscle fat fraction (VL MFF) that should be in the range >10% but <30%;
    9. Have used systemic corticosteroids for a minimum of 6 months immediately prior to the start of study treatment, with no significant change in dosage or dosing regimen (excluding changes related to body weight change) for a minimum of 6 months immediately prior to start of study treatment and a reasonable expectation that dosage and dosing regimen will not change significantly for the duration of the study.
    10. Subjects must be willing to use adequate contraception.
    Contraceptive methods must be used from Randomization Visit 3 through 3 months after the last dose of study drug, and include the following:
    • True abstinence (absence of any sexual intercourse), when in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g. calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.
    • Condom with spermicide and the female partner must use an acceptable method of contraception, such as an oral, transdermal, injectable or implanted steroid-based contraceptive, or a diaphragm or a barrier method of contraception in conjunction with spermicidal jelly such as for example cervical cap with spermicide jelly.
    1. Varones ambulantes de ≥6 años de edad en la aleatorización con los síntomas y signos clínicos característicos de la DMD (p. ej., debilidad muscular proximal, maniobra de Gowers, concentración sérica elevada de creatinina cinasa) ya presentes en la selección;
    2. Diagnóstico de DMD confirmado mediante pruebas genéticas;
    3. Capacidad de otorgar el asentimiento o consentimiento informado por escrito firmado por el paciente o el progenitor/tutor legal (según los reglamentos locales);
    4. Capacidad para completar 2 pruebas de subir cuatro escalones (S4E) en las evaluaciones de selección; los resultados de estas pruebas deberán estar en el rango de ±1 segundo entre ambas;
    5. Presentar un promedio de las 2 evaluaciones S4E de ≤8 segundos;
    6. Presentar un tiempo para levantarse del suelo de <10 segundos en la selección;
    7. Presentar una prueba muscular manual (PMM) del cuádriceps en la selección de ≥grado 3;
    8. Ser apto según el algoritmo funcional específico del protocolo predictivo de la fracción grasa del músculo vasto lateral (FGMVL), que deberá estar en el rango de >10 % pero <30 % (ver apartado 4.2.3);
    9. Haber tomado corticoesteroides sistémicos durante un mínimo de 6 meses inmediatamente antes del inicio del tratamiento del estudio, sin un cambio significativo en la posología o la pauta posológica (excluyendo los cambios relacionados con el cambio en el peso corporal) durante un mínimo de 6 meses inmediatamente antes del inicio del tratamiento del estudio y una expectativa razonable de que la posología y la pauta posológica no cambiarán de forma significativa durante la duración del estudio.
    10. Los pacientes deben estar dispuestos a utilizar anticonceptivos apropiados. Los métodos anticonceptivos se deberán emplear desde la aleatorización de la visita 3 hasta 3 meses después de la administración de la última dosis del fármaco del estudio. Entre los métodos anticonceptivos que se deberán emplear figuran los siguientes:
    • abstinencia completa (ausencia de coito) cuando concuerde con el estilo de vida preferido y habitual del paciente. La abstinencia periódica (por ejemplo, los métodos basados en el calendario, en la ovulación, en la postovulación y sintotérmico) y el coitus interruptus no constituyen métodos anticonceptivos aceptables;
    • condón con espermicida y uso por parte de las parejas (mujeres) de los pacientes de un método anticonceptivo aceptable, como anticonceptivos esteroideos orales, transdérmicos, inyectables o implantados, diafragma o un método anticonceptivo de barrera junto con un gel espermicida como, por ejemplo, el capuchón cervical con gel espermicida.
    E.4Principal exclusion criteria
    1. Have exposure to another investigational drug within 3 months prior to the start of study treatment;
    2. Have exposure to idebenone within 3 months prior to the start of study treatment;
    3. Have exposure to any dystrophin restoration product (e.g., Ataluren, Exon-skipping) within 6 months prior to the start of study treatment;
    4. Use of any pharmacologic treatment, other than corticosteroids, that might have had an effect on muscle strength or function within 3 months prior to the start of study treatment (e.g., growth hormone); Vitamin D, calcium, and any other supplements will be allowed;
    5. Have surgery that might have an effect on muscle strength or function within 3 months before study entry or planned surgery at any time during the study;
    6. Ankle joint contractures due to a fixed loss of ≥10 degrees of dorsiflexion from plantagrade assuming a normal range of dorsiflexion of 20 degree;
    7. Change in contracture treatment such as serial casting, contracture control devices, night splints, stretching exercises (passive, active, self) within 3 months prior to enrollment, or expected need for such intervention during the study;
    8. Have presence of other clinically significant disease, which, in the Investigator’s opinion, could adversely affect the safetyof the subject, making it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results;
    9. Have a diagnosis of other neurological diseases or presence of relevant somatic disorders that are not related to DMD;
    10. Have platelets count, White Blood Cell and Hemoglobin at screening <Lower Limit of Normal (LLN) (for abnormal screening laboratory test results (<LLN), the platelets count, White Blood Cell and Hemoglobin will be repeated once; if the repeat test result is still <LLN, then exclusionary);
    11. Have symptomatic cardiomyopathy or heart failure (New York Heart Association Class III or IV) or left ventricular ejection fraction <50% at screening;
    12. Have a current or history of liver disease or impairment; including but not limited to an elevated total bilirubin (i.e. > 1.5 x ULN), unless secondary to Gilbert disease or pattern consistent with Gilbert's;
    13. Have inadequate renal function, as defined by serum Cystatin C >2 x the upper limit of normal (ULN). If the value is >2 x ULN, the serum Cystatin C will be repeated once; if the repeated test result is still >2 x ULN, the subject should be excluded);
    14. Have a positive test for hepatitis B surface antigen, hepatitis C antibody, or human immunodeficiency virus at screening;
    15. Have a baseline corrected QT interval, Fridericia’s correction (QTcF) >450 msec, (as the mean of 3 consecutive readings 5 minutes apart) or history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia, or family history of long QT syndrome);
    16. Have a psychiatric illness/social situations rendering the potential subject unable to understand and comply with the muscle function tests and/or with the study protocol procedures;
    17. Have any hypersensitivity to the components of study medication;
    18. Have a sorbitol intolerance or sorbitol malabsorption, or have the hereditary form of fructose intolerance.

    For the subgroup of subjects who will perform the magnetic resonance imaging (MRI) and spetroscopy (MRS) (i.e., MR Cohort):
    19.Have contraindications to MRI or MRS (e.g., claustrophobia,
    metal implants, or seizure disorder).
    1. Exposición a otro fármaco en fase de investigación en los 3 meses anteriores al inicio del tratamiento del estudio;
    2. Exposición a idebenona en los 3 meses anteriores al inicio del tratamiento del estudio;
    3. Exposición a cualquier agente de reparación de la distrofina (p. ej., Ataluren, Exon-skipping) en los 6 meses anteriores al inicio del tratamiento del estudio;
    4. Uso de cualquier tratamiento farmacológico, excepto corticoesteroides, que pudiera tener un efecto sobre la fuerza o función muscular en los 3 meses anteriores al inicio del tratamiento del estudio (p. ej., hormona del crecimiento); se permitirá el uso de vitamina D, calcio y otros suplementos;
    5. Intervención quirúrgica que podría tener un efecto sobre la fuerza o función muscular en los 3 meses anteriores a la entrada en el estudio o intervención quirúrgica programada en cualquier momento durante el estudio;
    6. Contracturas de la articulación del tobillo debidas a una pérdida fija de ≥10 grados de dorsiflexión desde flexión plantar, partiendo de un rango normal de dorsiflexión de 20 grados;
    7. Cambio en el tratamiento de la contractura, como yeso seriado, dispositivos de control de la contractura, férulas nocturnas, ejercicios de estiramiento (pasivo, activo, propio) en los 3 meses anteriores a la inclusión, o se espera que tal intervención sea necesaria durante el estudio;
    8. Presencia de otra enfermedad clínicamente significativa que, en opinión del investigador, podría afectar negativamente a la seguridad del paciente, haciendo poco probable que se pudieran completar el curso de tratamiento o el seguimiento, o que podría afectar a la evaluación de los resultados del estudio;
    9. Diagnóstico de otras enfermedades neurológicas o presencia de trastornos somáticos relevantes que no estén relacionados con la DMD;
    10. Recuento plaquetario, leucocitario y de hemoglobina en la selección <del límite inferior de la normalidad (LIN) (para los resultados analíticos anómalos en la selección (<LIN), el recuento plaquetario, leucocitario y de hemoglobina se repetirá una vez; si la prueba repetida sigue estando <LIN, será excluyente);
    11.Miocardiopatía o insuficiencia cardíaca sintomática (clase III o IV de la New York Heart Association) o fracción de eyección ventricular izquierda <50 % en la selección;
    12. Antecedentes o presencia actual de enfermedad o insuficiencia hepática, incluidos, entre otros, el aumento de la bilirrubina total (es decir, >1,5 × el límite superior de la normalidad [LSN]), salvo que sea secundario al síndrome de Gilbert o se trate de un perfil o patrón coherente con el síndrome de Gilbert;
    13. Función renal inadecuada, definida por una concentración sérica de cistatina C >2 x LSN. Si el valor es >2 x LSN, se repetirá una vez la prueba de cistatina C en suero; si el resultado de la prueba repetida sigue siendo >2 x LSN, el paciente será excluido);
    14. Resultado positivo en la prueba de antígeno de superficie de la hepatitis B, anticuerpos contra la hepatitis C o virus de la inmunodeficiencia humana en la selección;
    15. Presentar un intervalo QT corregido, corrección de Fridericia (QTcF) >450 ms, (como la media de 3 lecturas consecutivas a intervalos de 5 minutos) o antecedentes de factores de riesgo adicionales de torsades de pointes (p. ej., insuficiencia cardíaca, hipopotasemia, o antecedentes familiares de síndrome de QT largo);
    16. Presentar una enfermedad psiquiátrica/situaciones sociales que hacen que el posible paciente sea incapaz de entender y realizar las pruebas de función muscular o los procedimiento del protocolo del estudio;
    17. Presentar hipersensibilidad a los componentes de la medicación del estudio;
    18. Presentar intolerancia al sorbitol o malabsorción del sorbitol o presentar la forma hereditaria de la intolerancia a la fructosa.
    Para el subgrupo de pacientes que se someterán a resonancia magnética (RM) y espectroscopia por resonancia magnética (ERM) (es decir, cohorte RM):
    19. Presentar contraindicaciones a la RM o ERM (p ej., claustrofobia, implantes metálicos, o trastorno convulsivo).
    E.5 End points
    E.5.1Primary end point(s)
    Mean change in 4SC before and after 18 months of treatment of givinostat versus placebo.
    Cambio medio en la prueba S4E antes y después de 18 meses de tratamiento con givinostat en comparación con placebo.
    E.5.1.1Timepoint(s) of evaluation of this end point
    18 months
    18 meses
    E.5.2Secondary end point(s)
    Key endpoints (all subjects):
    Mean change in time to rise from floor before and after 18 months of treatment of givinostat versus placebo;
    Mean change in 6MWT before and after 18 months of treatment of givinostat versus placebo;
    Mean change in muscle strength evaluated by knee extension, elbow flexion as measured by HHM, before and after 18 months of treatment of givinostat versus placebo.

    Key endpoints (MR cohort):
    • Mean change in fat fraction of vastus lateralis muscles comparing the MRS before and after 12 months of treatment of givinostat versus placebo;
    • Mean change in 4SC before and after 12 months of treatment of givinostat versus placebo;
    • Mean change in time to rise from floor before and after 12 months of treatment of givinostat versus placebo;
    • Mean change in 6MWT before and after 12 months of treatment of givinostat versus placebo;
    • Mean change in muscle strength evaluated by knee extension before and after 12 months of treatment of givinostat versus placebo;
    • Mean change in fat fraction of vastus lateralis muscles comparing the MRS before and after 18 months of treatment of givinostat versus placebo

    Safety endpoints:
    - Number of subjects experiencing treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) (Baseline through end of study [EOS]);
    - Type, incidence, and severity of TEAEs and SAEs (Baseline through EOS);
    - Changes from baseline to end of study of:
    o Vital signs and clinical laboratory tests (blood chemistry and hematology);
    o Respiratory function evaluated by forced vital capacity (FVC), forced expiratory volume at 1 second (FEV1), FVC/FEV1, Peak Expiratory Flow (PEF);
    o Cardiac function evaluated by ECG and ECHO;
    o Cognitive function evaluated by the Raven progressive matrices;
    o Weight, height, and body mass index (BMI).
    o Evaluation of acceptability/palatability of the oral suspension.

    Pharmacokinetic Endpoints:
    - Description of the PK of givinostat and its major metabolites:
    ITF2374 and ITF2375 in the subject population;
    - Identification of the relevant demographic and pathophysiological covariates influencing the PK of givinostat.

    Exploratory endpoints:
    • Mean changes before and after 12 months of treatment of givinostat versus placebo of:
    o time to 4SC;
    o time to rise from floor;
    o 6MWT;
    o muscle strength.
    • Mean changes before and after 12 and 18 months of treatment of givinostat as compared to placebo of:
    o time to walk/run 10 meters;
    o physical function as measured by NSAA;
    o PODCI scores.
    • Mean changes before and after 18 months of treatment of givinostat as compared to placebo of:
    o %-predicted 6MWT;
    o Only in the MR cohort: MRI parameters (e.g., fat fraction of thigh muscles, CSA of vastus lateralis and other thigh muscles).
    • Time to 10% persistent worsening in 6MWT (Baseline through end of study);
    • Proportion of subjects with ≥10% worsening in 6MWT at end of study;
    • Time to loss of standing (Baseline through end of study);
    • Proportion of subjects who loose ambulation during the study;
    • PK-PD analyses: relationships between metrics of exposure and efficacy/safety endpoints of givinostat.
    Criterios de valoración clave (todos los pacientes):
    • Cambio medio en el tiempo empleado en levantarse del suelo y después de 18 meses de tratamiento con givinostat en comparación con placebo;
    • Cambio medio en la prueba PM6M antes y después de 18 meses de tratamiento con givinostat en comparación con placebo;
    • Cambio medio en la fuerza muscular evaluada mediante la extensión de la rodilla y la flexión del codo, medidas mediante MM, antes y después de 18 meses de tratamiento con givinostat en comparación con placebo;
    Criterios de valoración clave (cohorte RM):
    • Cambio medio en la fracción grasa de los músculos vastos laterales comparando las EMR antes y después de 12 meses de tratamiento con givinostat en comparación con placebo;
    • Cambio medio en la prueba S4E y después de 12 meses de tratamiento con givinostat en comparación con placebo;
    • Cambio medio en el tiempo empleado en levantarse del suelo y después de 12 meses de tratamiento con givinostat en comparación con placebo;
    • Cambio medio en la prueba PM6M y después de 12 meses de tratamiento con givinostat en comparación con placebo;
    • Cambio medio en la fuerza muscular evaluada mediante la extensión de la rodilla antes y después de 12 meses de tratamiento con givinostat en comparación con placebo;
    • Cambio medio en la fracción grasa de los músculos vastos laterales comparando las EMR antes y después de 18 meses de tratamiento con givinostat en comparación con placebo.
    Criterios de valoración de la seguridad:
    • Número de pacientes que experimenta acontecimientos adversos surgidos durante el tratamiento (AAST) y acontecimientos adversos graves (AAG) (desde el inicio hasta el final del estudio [FDE]);
    • Tipo, incidencia y gravedad de los AAST y AAG (desde el inicio hasta el FDE);
    • Cambios desde el inicio hasta el final del estudio en:
    o Constante vitales y análisis clínicos (bioquímica sanguínea y hematología);
    o Función respiratoria evaluada mediante la capacidad vital forzada (FVC), el volumen espiratorio forzado en 1 segundo (FEV1), FVC/FEV1 y el flujo espiratorio máximo (PEF);
    o Función cardíaca evaluada mediante ECG y ECO;
    o Función cognitiva evaluada mediante las matrices progresivas coloreadas de Raven;
    o Peso, estatura e índice de masa corporal (IMC).
    • Evaluación de la aceptabilidad/agradabilidad de la suspensión oral.
    Criterios de valoración farmacocinéticos:
    • Descripción de la FC de givinostat y sus principales metabolitos: ITF2374 e ITF2375 en la población de pacientes;
    • Identificación de los datos demográficos y las covariables fisiopatológicas relevantes que influyen en la FC de givinostat.
    Criterios de valoración exploratorios:
    • Cambios medios antes y después de 12 meses de tratamiento con givinostat en comparación con placebo en:
    o tiempo empleado en la prueba S4E;
    o tiempo empleado en levantarse del suelo;
    o PM6M;
    o fuerza muscular.
    • Cambios medios antes y después de 12 y 18 meses de tratamiento con givinostat en comparación con placebo en:
    o tiempo empleado en caminar/correr 10 metros;
    o función física medida mediante la NSAA;
    o Puntuaciones de la PODCI.
    • Cambios medios antes y después de 18 meses de tratamiento con givinostat en comparación con placebo en:
    o % predictivo de la PM6M;
    o Solamente en la cohorte RM: Parámetros de RM (p. ej., fracción grasa de los músculos del muslo, AT de músculo vasto lateral y otros músculos del muslo).
    • Tiempo hasta un empeoramiento persistente del 10 % en la PM6M (desde el inicio hasta el final del estudio);
    • Proporción de pacientes con un empeoramiento ≥10 % en la PM6M al final del estudio;
    • Tiempo hasta perder la posición vertical (desde el inicio hasta el final del estudio);
    • Proporción de pacientes que pierden la ambulación durante el estudio;
    • Análisis de FC-FD; relaciones entre las mediciones de exposición y los criterios de valoración de eficacia/seguridad de givinostat.
    E.5.2.1Timepoint(s) of evaluation of this end point
    timepoint given in endpoint
    Definidos en los criterios de valoración
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Quality of life and daily activities
    Calidad de vida y actividades diarias
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned4
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA24
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Belgium
    Canada
    France
    Germany
    Israel
    Italy
    Netherlands
    Spain
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Última visita del último paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months7
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 192
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 150
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 42
    F.1.2Adults (18-64 years) No
    F.1.2.1Number of subjects for this age range: 0
    F.1.3Elderly (>=65 years) No
    F.1.3.1Number of subjects for this age range: 0
    F.2 Gender
    F.2.1Female No
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    male paediatric subjects aged ≥6 years
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state12
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 100
    F.4.2.2In the whole clinical trial 192
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    A follow up visit will be performed 4 weeks after the last dose is administered (± 7 days) and only in cases where the subject or parent/legal guardian do not provide assent/consent to participate in long-term study.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-02-10
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-01-31
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2022-02-22
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA